GeoVax Labs Investor Relations Material

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which focuses on the development of human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle (VAP) vaccine platform. The company develops vaccines for the treatment of infectious diseases, such as malaria and tuberculosis; and immunotherapies for cancers. It also develops platforms containing novel antigens against various pathogens including hepatitis B virus, hepatitis C virus, influenza virus, Dengue fever virus and Plasmodium falciparum parasite; as well as replication-competent viruses for select human cancers.